


National HIV Behavioral Surveillance (NHBS): What we're doing in Denver



SAFER • HEALTHIER • PEOPLE™



NHBS Overview

- On-going surveillance activities conducted nationally in rotating 12-month cycles in three populations at high risk for HIV
 - Men who have sex with men (MSM)
 - Injection drug users (IDU)
 - Heterosexuals at risk (HET)
- Standardized core questionnaire across sites and populations
- A minimum of 500 persons per metropolitan area will be interviewed during each cycle
- Anonymous and voluntary

NHBS Objectives

1. Assess the prevalence and trends in risk behaviors including sexual and drug-use risk behaviors
2. Assess the prevalence of and trends in HIV testing behaviors
3. Assess the exposure to and use of prevention services
4. Assess the impact of prevention services on behavior
5. Identify prevention-service gaps and missed opportunities for prevention
6. Assess the prevalence of and trends in HIV seroprevalence
7. Assess behaviors associated with serostatus


Current NHBS Sites (21 sites)



National HIV Behavioral Surveillance System

CDC funded, 21 participating sites

12 month cycles in 3 target populations



NHBS-IDU2 (2009)

- Respondent-driven sampling
- Eligibility criteria:
 - At least 18 years of age
 - Lives in the participating MSA
 - Able to complete the interview in English or Spanish
 - Not previously participated in NHBS-IDU2
 - Has injected drugs (that were not prescribed for them) within the past 12 months
- Interviewer administered survey via handheld ipaq (\$25 incentive)
- HIV and HCV testing (\$25 incentive)


Respondent-driven sampling

1. Starts with a limited number of non-randomly selected “seeds”
2. “Seeds” complete surveillance activities
3. Selected “seeds” are given referral cards and asked to recruit up to 5 people they know who are IDU
4. These persons, in turn, complete surveillance activities and are asked to recruit others
5. Process continues until sample size is reached

Formative Research Goals

- Identify information on major IDU networks
- Obtain information relevant to field logistics
- Ensure that local prevention questions are relevant to local HIV prevention activities
- Ensure that during data collection, an adequate number of eligible IDUs are recruited to reflect the broader IDU community
- Identify potential initial “seeds”

Denver NHBS Data



NHBS-IDU: Gender

	IDU1 (2005-2006) N=519 N (%)	IDU2 (2009) N=432 N (%)
Male	371 (71.5)	296 (68.7)
Female	184 (28.5)	134 (31.1)
Transgender		1 (0.2)

NHBS-IDU: Race/Ethnicity

	IDU1 (2005-2006) N=519 N (%)	IDU2 (2009) N=431 N (%)
White, non-Hispanic	251 (48.4)	221 (51.5)
Black, non-Hispanic	77 (14.8)	55 (12.8)
Hispanic	145 (27.9)	116 (27.0)
Other*	46 (8.9)	37 (8.6)

NOTE: * includes Asian, Pacific Islander, American Indian, Alaskan Native

NHBS-IDU: Age

	IDU1 (2005-2006) N=519 N (%)	IDU2 (2009) N=431 N (%)
18 – 24	34 (6.6)	28 (6.5)
25 – 34	87 (16.8)	83 (19.3)
35 – 44	145 (27.9)	107 (24.8)
45 – 54	200 (38.5)	121 (28.1)
≥ 55	53 (10.2)	92 (21.3)

HIV and HCV Testing

- Voluntary and anonymous
- \$25 incentive
- HIV Testing
 - Rapid OraQuick on oral specimen
 - Confirmatory WB on serum specimen
- HCV Testing
 - Standard Ortho EIA on serum specimen
 - Evaluating rapid HCV test (oral swab and finger prick)

IDU2: HIV Testing Results

	IDU2 (2009) N=428 N (%)
Negative for HIV	407 (95.1)
Positive for HIV	20 (4.7)
Indeterminant	1 (0.2)

IDU2: HCV Testing Results

	IDU2 (2009) N=429 N (%)
Collected blood for HCV test	400 (93.2)
Negative for HCV	106 (26.5)
Positive for HCV	291 (72.8)
Unknown	3 (0.7)

Local Questions

- Exposure to local prevention activities
 - Project SAFE (ARTS, University of CO)
 - RUG (Regional Users Group)
 - Drop-in Center/Harm Reduction Action Center
 - Sisters of Color “Intersections”
- First injection experiences
- Experiences with law enforcement
- Syringe access
- Methadone clinics
- Overdose
- Abscesses

IDU2: Bought syringes from pharmacy in past 12 months?

	IDU2 (2009) N=425 N (%)
Yes	369 (86.8)
No	56 (13.2)

IDU2: How many difference pharmacies bought syringes from in past 12 months?

	IDU2 (2009) N=425 N (%)
Always go to same pharmacy	157 (36.9)
2 to 3 different pharmacies	182 (42.8)
More than 4 pharmacies	30 (7.1)
Did not buy syringes	56 (13.2)

IDU2: How often purchased syringes in past 12 months?

	IDU2 (2009) N=425 N (%)
Daily	14 (3.3)
Weekly	138 (32.5)
Every couple of weeks	113 (26.6)
Every couple of months	103 (24.2)
Did not buy syringes	57 (13.4)

IDU2: How many times pharmacies refused to sell syringes in past 12 months?

	IDU2 (2009) N=425 N (%)
Never	262 (61.6)
More than 10 times	20 (4.7)
5 – 10 times	20 (4.7)
Less than 5 times	67 (15.8)
Did not buy syringes	56 (13.2)

IDU2: Obtained syringes from a needle exchange program in Denver?

	IDU2 (2009) N=425 N (%)
Yes	68 (16.0)
No	357 (84.0)

IDU2: How would access to new sterile syringes and injection kits affect drug use?

	IDU2 (2009) N=425 N (%)
Increase drug use	39 (9.2)
Decrease drug use	15 (3.5)
No change	371 (87.3)

IDU2: Ever been a client of methadone clinic?

	IDU2 (2009) N=425 N (%)
Yes	237 (55.8)
No	188 (44.2)

IDU2: Last time in treatment at methadone clinic?

	IDU2 (2009) N=425 N (%)
Currently in treatment	90 (21.2)
In the last year	44 (31.5)
Within the last 2 to 5 years	68 (16.0)
Longer than 5 years	35 (8.2)
Never in treatment	188 (44.2)

IDU2: Main reason on methadone

	IDU2 (2009) N=90 N (%)
Don't want to be dope sick	20 (22.0)
To get stability	23 (25.6)
To quit using drugs	38 (42.2)
Reduce size of habit	5 (5.6)
For custody of children	2 (2.2)

IDU2: Ever tried to detox on own?

	IDU2 (2009) N=425 N (%)
Yes	329 (77.4)
No	96 (22.6)

IDU2: How many times had potentially deadly reaction or overdose?

	IDU2 (2009) N=425 N (%)
Never	157 (36.9)
Once	57 (13.4)
Twice	65 (15.3)
3 or more	146 (34.3)

IDU2: Last overdose intentional or accidental?

	IDU2 (2009) N=425 N (%)
Intentional	15 (3.5)
Accidental	252 (59.3)
Never	158 (37.2)

Next Steps....

- Continue to share data with local stakeholders, community based organizations, and local care and prevention planning groups
- Begin surveillance activities for the next cycle with heterosexuals at risk
- Start planning for the third round of NHBS!

Many thanks to...

- CDC
- CDPHE
- DPH NHBS team
 - Mark Thrun
 - Toby LeRoux
 - Chuck Chen
 - Theresa Mickiewicz
 - NHBS Interviewers

Questions?



Alia Al-Tayyib, PhD, MSPH
Denver Public Health
605 Bannock St
Denver, CO 80204
Alia.Al-Tayyib@dhha.org
303-602-3601